Management of menopause

Minerva Ginecologica

Volumn 58, Issue 2, 2006, Pages 137-152

  Castelo Branco, C ^a,b   Rostro, F ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Hormone replacement therapy; Menopause, diagnosis; SERMs, CAM

Indexed keywords

ALENDRONIC ACID; BENZOTHIOPHENE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; GESTAGEN; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHONIC ACID DERIVATIVE; PHYTOESTROGEN; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID;

AGING; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CUTANEOUS PARAMETERS; DOSE RESPONSE; DRUG ACTIVITY; ENDOMETRIUM HYPERPLASIA; FEMALE GENITAL SYSTEM; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HORMONAL THERAPY; HUMAN; MEDICAL ASSESSMENT; MENOPAUSAL SYNDROME; META ANALYSIS; MORBIDITY; OSTEOPOROSIS; OVARY FUNCTION; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; VAGINA ATROPHY; VAGINITIS; VASOMOTOR DISORDER; VERTEBRA FRACTURE;

BREAST DISEASES; CARDIOVASCULAR DISEASES; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; MENOPAUSE; OSTEOPOROSIS; WOMEN'S HEALTH;

EID: 33646573674     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Executive Summary. Stage of Reproductive Aging Workshop (STRAW) Park City, Utah, July 2001. Menopause 2001;8:402-7.
2. Sherman S. Defining the menopausal transition. Am J Med 2005;118 Suppl 12B:3S3-S7S.
3. Binfa L, Castelo-Branco C, Blümel JE, Cancelo MJ, Bonilla H, Muñoz I et al. Influence of psycho-social factors on Climacteric Symptoms. Maturitas 2004;48:425-31.
4. Gold EB, Sternfeld B, Kelsey JL, Brown C, Mouton C, Reame N et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-73.
5. Gold EB, Block G, Crawford S, Lachance L, FitzGerald G, Miracle H et al. Lifestyle and demographic factors in relation to vasomotor symptoms baseline results from the Study of Women's Health Across the Nation. Am J Epidemiol 2004;159:1189-99.
6. Sherman S, Miller H, Nerurkar L, Schiff I. Research opportunities for reducing the burden of menopause-related symptoms. Am J Med 2005;118 Suppl 2:166-71.
7. Castelo-Branco C, Durán M, Puig M, Vanrell JA. Compliance with hormone replacement therapy. J Obstet Gynecol 1995;15:204-5.
8. Blümel JE, Castelo-Branco C, Kerrigan N, Cancelo MJ, Blümel B, Haya J et al. Influences of hormone replacement therapy on postmenopausal women's health perceptions. Menopause 2003;10:235-40.
9. Castelo-Branco C, Palacios S, Mostajo D, Tobar C, von Heide S. Menopausal transition in Movima women, a Bolivian native-american. Maturitas 2005;51:380-5.
10. Kopernik G, Shoham Z. Tools for making correct decisions regarding hormone therapy. Part II. Organ response and clinical applications. Fertil Steril 2004;81:1458-77.
11. Taylor Nelson Sofres (TNS). Intersearch Corporation. Incidence and Persistency of Estrogen Replacement. May 17, 2000.
12. Palacios S, Ferrer-Barriendos J, Parrilla JJ, Castelo-Branco C, Manubens M, Alberich X et al. Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale. Med Clin (Barc) 2004;122:205-11.
13. Farrell E. Medical choices available for management of menopause. Best Prac Res Clin Endocrinol Metab 2003;17:1-16.
14. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86; discussion 123-33.
15. WHO. Technical report series. Menopause. Geneva: WHO; 1966. p. 236-42.
16. Sturdee DW, Wilson KA, Pipili E, Crocker AD. Physiological aspects of menopausalhotflush. BMJ 1978;2:79-80.
17. Freedman R. Physiology of hot flushes. Am J Hum Biol 2001;13:453-64.
18. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-18.
19. Stearns V, Ullmer L, Lopez JF, Smith Y, Issacs C, Hayes DF. Hot flushes. Lancet 2002;360:1851-61.
20. NIH State-of-the-Science Panel. National Institutes of Health State-of-the-Science Conference Statement: Management of Menopause-Related Symptoms. Ann Intern Med 2005;142:1003-13.
21. Rossouw JE, Anderson GL, Prentice RL, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
22. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
23. Shumaker SA, Legault C, Kuller L, Rapp SR, Thai L, Lane DS et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women Women's Health Initiative Memory Study. JAMA 2004;291:2947-58.
24. Blümel JE, Castelo-Branco C, Binfa L, Aparicio R, Mamani L. A scheme of combined oral contraceptives for women over 40. Menopause 2001;8:286-9.
25. Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. BJOG 1998;105:904-11.
26. Landgren BM, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002;109:1109-14.
27. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104: 824-36.
28. Wyon Y, Wijma KMA, Nedstrand E, Hammar M. A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women. Climacteric 2004;7:153-64.
29. Freedman RR, Woodward S, Brown B, Javaid JI, Pandey GN. Biochemical and thermoregulatory effecs of behavioural treatments for menopausal hot flashes. Menopause 1995;2:211-8.
30. Irvin JH, Domar AD, Clark C, Zuttermeister PC. Friedman R. The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol 1996;17:202-7.
31. Lindh-Astrand L, Nedstrand E, Wyon Y, Hammar M. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas 2004;48:97-105.
32. Aiello EJ, Yasui Y, Tworoger SS, Ulrich CM, Irwin ML, Bowen D et al. Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. Menopause 2004;11:382-8.
33. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. Management of postmenopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52 Suppl 1:S46-52.
34. Baker V. Alternatives to oral oestrogen replacement: transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am 1994;21:271-97.
35. Palacios S, Castelo-Branco C, Cancelo MJ, Vazquez F. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 2005;50:98-104.
36. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-63.
37. Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80.
38. Blümel JE, Castelo-Branco C, Cancelo M, Romero H, Aprikian D, Sarrá S. Impairment of sexual activity in middle-aged women. Menopause 2004;11:78-81.
39. Castelo-Branco C, Blumel JE, Araya H, Riquelme R, Castro G, Haya J et al. Prevalence of sexual dysfunction in a cohort of middle-age women. Influences of menopause and hormone replacement therapy. J Obstet Gynaecol 2003;23:426-30.
40. Willhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy 2001;21:464-80.
41. Sarrel PM. Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. J Womens Health Gend Based Med 2000;9 Suppl 1:S25-32.
42. Erratum in: J Womens Health Gend Based Med 2001;10:91.
43. Berman JR, Goldstein I. Female sexual dysfunction. Urol Clin N Am 2001;28:405-16.
44. Freedman MA. Quality of life and menopause: the role of estrogen. J Womens Health (Larchmt) 2002;11:703-18.
45. Bachmann GA, Leiblum SR, Grill J. Brief sexual inquiry in gynecological practice. Obstet Gynecol 1989;73 (3 Pt 1):425-7.
46. Alexander JL, Kotz K, Dennerstein L, Kutner SJ, Wallen K, Notelovitz M. The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause 2004;11:749-65.
47. Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet 2005;366:409-13.
48. Zumoff B, Strain GW, Miller LK , Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995;80:1429-30.
49. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832-8.
50. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000;85:645-51.
51. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol'ss effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36.
52. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
53. Lobo R, Rosen RC, Yang H-M, Bock B, Van der Hoop R. Comparative effects of oral esterified estrogens with and without methyl testosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-52.
54. Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:161-8.
55. Blumel JE, Castelo-Branco C, Binfa L, Gramegna G, Tacla X, Aracena B et al. Quality of life after the menopause: a population study. Maturitas 2000;34:17-23.
56. Castelo-Branco C, Colodrón M, Rostro F, Duran M. Skin and HRT. Ginecol y Obst Clin 2005;6:191-200.
57. Castelo-Branco C, Figueras F, Martinez de Osaba MJ, Vanrell JA. Facial wrinkling in postmenopausal women. Effects of smoking status and hormone replacement therapy. Maturitas 1998;29:75-86.
58. Blümel JE, Castelo-Branco C, Cancelo MJ, Córdova A, Binfa L, Bonilla H et al. Relationship between psychological complaints and vasomotor symptoms during climacteric. Maturitas 2004;49:205-10.
59. Castelo-Branco C, Blümel JE, Figueras F. [Hormone replacement therapy and antidepressants during menopause] Rev Chil Obstet Ginecol 1998;63:321-7. Spanish.
60. Dennerstein L, Guthrie JR, Clark M, Lehert P, Henderson VW. A population-based study of depressed mood in the middle-aged, Australian-born women. Menopause 2004;11:563-8.
61. Castelo-Branco C. Management of osteoporosis. An overview. Drugs Aging 1998;12 Suppl 1:25-32.
62. McClung MR. Prevention and management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2003;17:53-71.
63. Castelo-Branco C, Figueras F, Sanjuan A, Vicente JJ, Martínez de Osaba MJ, Pons F et al. Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause 1999;6:307-11.
64. Castelo-Branco C, Rovira M, Pons F, Durán M, Sierra J, Vives A et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 1996;23:307-12.
65. Castelo-Branco C, Martínez de Osaba MJ, Pons F, Casals E, Sanjuán A, Vicente JJ et al. Ossein-hydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement therapy. J Reprod Med 1999;44:241-6.
66. Castelo-Branco C, Vicente JJ, Pons F, Martínez de Osaba MJ, Casals E, Vanrell JA. Bone mineral density in young hypothalamic amenorrheic women treated with oral contraceptives containing different doses of ethinyl estradiol. J Reprod Med 2001;46:875-9.
67. Figueras F, Castelo-Branco C, Pons F, Sanjuán A, Vanrell JA. Effect of continuous and sequential oral estrogen-progestogen replacement regimens on postmenopausal bone loss: a two years prospective study. Eur J Obstet Gynecol Reprod Biol 2001;99:261-5.
68. Manson JE, Martin KA. Postmenopausal hormone-replacement therapy. N Engl J Med 2001;345:34-40.
69. Critchley H, Gebbie A, Beral V. Menopause and hormone replacement. London: RCOG Press; 2004.
70. Andrews H, Christie B, Colledge N, Gallacher S, Glasier A, MacDonald J. Consensus Statement. J R Coll Physicians Edinb 2004;34 Suppl 13:2-3.
71. Recker RR, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000;15:1965-73.
72. Uusi-Rasi K, Sievanen H, Pasanen M, Oja P, Vuori I. Association of physical activity and calcium intake with the maintenance of bone mass in premenopausal women. Osteoporos Int 2002;13:211-7.
73. Jackson RD, LaCroix AZ, Gass M, Wallace MB, Robbins J, Lewis CE et al. and the Woman's Health Iniciative Investigators. N Engl J Med 2006;354:669-83.
74. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in post-menopausal women. N Engl J Med 1997;337:1641-7.
75. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-45.
76. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K et al. Raloxifene and cardiovascular events in osteoporotic post-menopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.
77. Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf 2005;28:721-30.
78. Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD et al. A meta-analysis of etidronate for the treatment of post-menopausal osteoporosis. Osteoporos Int 2001;12:140-51.
79. Blümel JE, Castelo-Branco C, De la Cuadra G, MacIver L, Moreno M, Haya J. Alendronate daily, weekly in conventional tablets and weekly in enteric tablets, preliminary study on the effects in bone turnover markers and incidence of side effects. J Obstet Gynaecol 2003;23:278-81.
80. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis. JAMA 1997;277:1159-64.
81. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
82. Harris S, Watts N, Genant H, McKeever CD, Hangartner T, Keller M et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52.
83. Delmas PD, Recker RR, Chestnut CH 3rd, Skag A, Stakkestad JA, Emkey R et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8.
84. Chesnut H 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S et al. A randomized trial of nasal spray salmon calcitonin in post-menopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. Am J Med 2000;109: 267-76.
85. Delmas P. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis. Osteoporos Int 2005;16 Suppl 1:516-9.
86. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
87. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley Da, Harris St et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
88. Kuter I. Breast cancer. In: Carlson K, Eisenstat S, Frigoletto F, Schiff I editors. Primary Care of Women. St. Louis: Mosby; 2002. p. 227-9.
89. Norman RJ, MacLennan AH. Current status of hormone therapy and breast cancer. Hum Reprod Update 2005;11:541-3.
90. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
91. Erratum in: Lancet 1997;350:1484.
92. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
93. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
94. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al. The effect of raloxifene on risk of breast cancer in post-menopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
95. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW et al. Continued breast cancer risk reduction in post-menopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34.
96. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D et al. Continuing outcomes relevant to Evista: breast cancer incidence in post-menopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61.
97. Gompel A, Siromachkova M, Lombet A, Kloosterboer HJ, Rostene W. Tibolone actions on normal and breast cancer cells. Eur J Cancer 2000;36 Suppl 4:S76-S77.
98. Bruce D, Robinson J, Rymer J. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric 2004;7:261-6.
99. Palomba S, Di Carlo C, Morelli M, Russo T, Noia R, Nappi C et al. Effect of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy. Maturitas 2003;45:267-73.
100. Chen FP, Lee N, Wang CH, Cherng WJ, Soong YK. Effects of hormone replacement therapy of cardiovascular risk factors in post-menopausal women. Fertil Steril 1998;69:267-73.
101. Ossewaarde ME, Bots ML, Bak AA, Van Der Schouw YT, Witteman JC, Planellas J et al. Effect of hormone replacement therapy on lipids on peri-menopausal and early post-menopausal women. Maturitas 2001;39:209-16.
102. Ylikorkala O, Lim P, Caubel P. Effect of serum lipid profiles of continuous combined 17b-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 2000;22:622-6.
103. Grodstein F, Manson JE, Colditz GA, Willen WC, Speizer FE, Stampfer MJ. A prospective, observational study of post-menopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
104. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Post-menopausal oestrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
105. Stampfer MJ, Colditz GA, Willen WC, Manson JE, Rosner B, Speizer FE et al. Post-menopausal oestrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991:325:756-62.
106. Hu FB, Stampfer MJ, Manson JE, Grodstein F, Colditz GA, Speizer FE et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000;343:530-7.
107. Creatsas G, Christodoulakos G, Lambrinoudaki I. Cardiovascular disease: screening and management of the a-symptomatic high-risk post-menopausal woman. Maturitas 2005;52:32-7.
108. Grady D, Weuger NK, Herrington D, Khan S, Furberg C, Hunninghake D et al. Heart and Oestrogen/Progestin Replacement Study. Ann Intern Med 2000;132:689-96.
109. Magliano D, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 2006;113:5-14.
110. Welty FK. Preventing clinically evident coronary heart disease in the post-menopausal women. Menopause 2004;11:484-94.